Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of concomitant Philadelphia chromosome-positive and CRLF2-rearranged B-cell ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNicholas J. ShortThe University of Texas MD Anderson Cancer CenterNDNaval DaverThe University of Texas MD Anderson Cancer CenterMRMichael RothThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Overview

Retrospective review shows chemotherapy and targeted therapy outcomes in high-risk B-cell ALL with dual mutations, indicating poor prognosis.

Key Points

  • This research aims to evaluate the outcomes of patients with concomitant Philadelphia chromosome-positive and CRLF2-rearranged B-cell acute lymphoblastic leukemia.
  • Retrospective review of patient records at MD Anderson Cancer Center (2014–2022)
  • Included patients with B-ALL having both Ph+ and CRLF2 rearrangements
  • Recorded treatment regimens of chemotherapy, immunotherapy, and kinase inhibitors
  • Out of 8 patients, 6 were newly diagnosed and 2 had relapsed/refractory disease
  • 1-year event-free survival (EFS) and overall survival (OS) rates were 66% and 83% for newly diagnosed patients
  • Complete remission achieved in 50% of newly diagnosed patients after initial treatment

Cite This Study

Short et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2cahttps://doi.org/10.1182/blood-2025-6834
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genetic characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients with CRLF2 rearrangements2025
  2. 2Pediatric B-lineage acute lymphoblastic leukemia with CRLF2 rearrangements. Own experience in molecular genetic diagnostics and patient monitoring2025
  3. 3Pediatric B-lineage acute lymphoblastic leukemia with CRLF2 rearrangements. Own experience in molecular genetic diagnostics and patient monitoring2025
  4. 4Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation2026
  5. 5Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia2026